{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:52:22Z","timestamp":1777542742252,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002905","name":"Ministerio de Salud y Protecci\u00f3n Social","doi-asserted-by":"publisher","award":["PI17\/01981"],"award-info":[{"award-number":["PI17\/01981"]}],"id":[{"id":"10.13039\/501100002905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00428-019-02593-x","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T18:10:32Z","timestamp":1561486232000},"page":"445-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype"],"prefix":"10.1007","volume":"475","author":[{"given":"Jorge","family":"Rebola","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Blanca","sequence":"additional","affiliation":[]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Vanessa","family":"Henriques","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Lobato-Faria","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-8164","authenticated-orcid":false,"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"2593_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005392-199909010-00019","volume":"162","author":"S Holm\u00e4ng","year":"1999","unstructured":"Holm\u00e4ng S, Hedelin H, Anderstr\u00f6m C, Holmberg E, Busch C, Johansson SL (1999) Recurrence and progression in low grade papillary urothelial tumors. J Urol 162:702\u2013707","journal-title":"J Urol"},{"key":"2593_CR2","doi-asserted-by":"publisher","first-page":"239.e1","DOI":"10.1016\/j.urolonc.2018.01.018","volume":"36","author":"D D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea D, Abufaraj M, Susani M et al (2018) Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol Oncol Semin Orig Investig 36:239.e1\u2013239.e7. \nhttps:\/\/doi.org\/10.1016\/j.urolonc.2018.01.018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2593_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larr\u00e9 S, di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmstr\u00f6m PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus calmette-gu\u00e9rin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67:74\u201382","journal-title":"Eur Urol"},{"key":"2593_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/path.1711660107","volume":"166","author":"AH Mulder","year":"1992","unstructured":"Mulder AH, Van Hootegem JCSP, Sylvester R et al (1992) Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle related nuclear antigen (Ki67). J Pathol 166:37\u201343","journal-title":"J Pathol"},{"key":"2593_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/cncr.10822","volume":"95","author":"Y Yan","year":"2002","unstructured":"Yan Y, Andriole GL, Humphrey PA, Kibel AS (2002) Patterns of multiple recurrences of superficial (Ta\/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer. 95:1239\u20131246","journal-title":"Cancer."},{"key":"2593_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","volume":"46","author":"A Lopez-Beltran","year":"2004","unstructured":"Lopez-Beltran A, Montironi R (2004) Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46:170\u2013176","journal-title":"Eur Urol"},{"issue":"s218","key":"2593_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/03008880802325226","volume":"42","author":"A Lopez-Beltran","year":"2008","unstructured":"Lopez-Beltran A (2008) Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol 42(s218):95\u2013109","journal-title":"Scand J Urol Nephrol"},{"key":"2593_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2016","unstructured":"Babjuk M, B\u00f6hle A, Burger M et al (2016) EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update. Eur Urol 71:447\u2013461","journal-title":"Eur Urol"},{"key":"2593_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 70:106\u2013119","journal-title":"Eur Urol"},{"key":"2593_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/fon.09.50","volume":"5","author":"L Cheng","year":"2009","unstructured":"Cheng L, Zhang S, Davidson D, MacLennan G, Koch M, Montironi R, Lopez-Beltran A (2009) Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 5:843\u2013857","journal-title":"Future Oncol"},{"key":"2593_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","volume":"72","author":"W Choi","year":"2017","unstructured":"Choi W, Ochoa A, McConkey DJ et al (2017) Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol 72:354\u2013365","journal-title":"Eur Urol"},{"key":"2593_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1073\/pnas.1120605109","volume":"109","author":"JP Volkmer","year":"2012","unstructured":"Volkmer JP, Sahoo D, Chin RK (2012) Three differentiation states risk-stratify bladder cancer into distinct subtypes. PNAS 109:2078\u20132083","journal-title":"PNAS"},{"key":"2593_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B (2016) Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12:105\u2013117","journal-title":"EBioMedicine"},{"issue":"10061","key":"2593_CR14","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstr\u00f6m PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet. 388(10061):2796\u20132810","journal-title":"Lancet."},{"key":"2593_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.hoc.2014.11.003","volume":"29","author":"DJ McConkey","year":"2015","unstructured":"McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CPN (2015) Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 29:377\u2013394","journal-title":"Hematol Oncol Clin North Am"},{"key":"2593_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrurol.2014.129","volume":"11","author":"W Choi","year":"2014","unstructured":"Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ (2014) Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11:400\u2013410","journal-title":"Nat Rev Urol"},{"key":"2593_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","volume":"11","author":"B Czerniak","year":"2016","unstructured":"Czerniak B, Dinney C, McConkey D (2016) Origins of bladder cancer. Annu Rev Pathol Mech Dis 11:149\u2013174","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2593_CR18","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","volume":"13","author":"L Dyrskjot","year":"2007","unstructured":"Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AMK, Jensen JL, Jensen KME, Marcussen N, Orntoft TF (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13:3545\u20133551","journal-title":"Clin Cancer Res"},{"key":"2593_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, H\u00f8yer S, Ulh\u00f8i BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, H\u00f6glund M, Birkenkamp-Demtr\u00f6der K, Fristrup N, Borre M, Hartmann A, St\u00f6hr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstr\u00f6m PU, Malats N, Real FX, Zwarthoff EC, \u00d8rntoft TF, Dyrskj\u00f8t L (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27\u201342","journal-title":"Cancer Cell"},{"key":"2593_CR20","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18:3377\u20133386","journal-title":"Clin Cancer Res"},{"key":"2593_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","volume":"183","author":"G Sj\u00f6dahl","year":"2013","unstructured":"Sj\u00f6dahl G, L\u00f6vgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, M\u00e5nsson W, Lindgren D, Fern\u00f6 M, Liedberg F, H\u00f6glund M (2013) Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 183:681\u2013691","journal-title":"Am J Pathol"},{"key":"2593_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","volume":"68","author":"O Patschan","year":"2015","unstructured":"Patschan O, Sjdahl G, Chebil G et al (2015) A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 68:824\u2013832","journal-title":"Eur Urol"},{"key":"2593_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0136688","volume":"10","author":"D Dhawan","year":"2015","unstructured":"Dhawan D, Paoloni M, Shukradas S et al (2015) Comparative gene expression analyses identify luminal and basal subtypes of canine invasive urothelial carcinoma that mimic patterns in human invasive bladder cancer. PLoS One 10:1\u201315","journal-title":"PLoS One"},{"key":"2593_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"DJ McConkey","year":"2016","unstructured":"McConkey DJ, Choi W, Shen Y et al (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-na\u00efve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisp. Eur Urol 69:855\u2013862","journal-title":"Eur Urol"},{"key":"2593_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0179602","volume":"12","author":"D Sikic","year":"2017","unstructured":"Sikic D, Keck B, Wach S et al (2017) Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One 12:1\u201313","journal-title":"PLoS One"},{"key":"2593_CR26","doi-asserted-by":"publisher","unstructured":"McConkey DJ, Choi W. (2018) Molecular subtypes of bladder cancer. Curr Oncol Rep 2018 20(10):77. doi: \nhttps:\/\/doi.org\/10.1007\/s11912-018-0727-5","DOI":"10.1007\/s11912-018-0727-5"},{"key":"2593_CR27","first-page":"1","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA et al (2017) Bladder cancer. Nat Rev Dis Prim 3:1\u201319","journal-title":"Nat Rev Dis Prim"},{"key":"2593_CR28","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","volume":"21","author":"J Kim","year":"2015","unstructured":"Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, Kwiatkowski DJ (2015) Invasive bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res 21:4514\u20134524","journal-title":"Clin Cancer Res"},{"key":"2593_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ajur.2016.09.009","volume":"3","author":"DJ McConkey","year":"2016","unstructured":"McConkey DJ, Choi W, Ochoa A, Dinney CPN (2016) Intrinsic subtypes and bladder cancer metastasis. Asian J Urol 3:260\u2013267","journal-title":"Asian J Urol"},{"key":"2593_CR30","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. PNAS 111:3110\u20133115","journal-title":"PNAS"},{"key":"2593_CR31","doi-asserted-by":"publisher","first-page":"80164","DOI":"10.18632\/oncotarget.13284","volume":"7","author":"AE Ochoa","year":"2016","unstructured":"Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey D (2016) Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget 7:80164\u201380174","journal-title":"Oncotarget"},{"key":"2593_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.eururo.2014.05.006","volume":"66","author":"DJ McConkey","year":"2014","unstructured":"McConkey DJ, Choi W, Dinney CPN (2014) New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 66:609\u2013610","journal-title":"Eur Urol"},{"issue":"244","key":"2593_CR33","doi-asserted-by":"publisher","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","volume":"6","author":"S Rebouissou","year":"2014","unstructured":"Rebouissou S, Bernard-pierrot I, De RA et al (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6(244):244ra91. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3008970","journal-title":"Sci Transl Med"},{"key":"2593_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CPN, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165","journal-title":"Cancer Cell"},{"key":"2593_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"JN Weinstein","year":"2014","unstructured":"Weinstein JN, Akbani R, Broom BM et al (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Cancer genome atlas research network. Nature 507:315\u2013322","journal-title":"Nature"},{"key":"2593_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/path.5230","volume":"247","author":"G Sj\u00f6dahl","year":"2019","unstructured":"Sj\u00f6dahl G, Jackson Chelsea L, Bartlett J, Robert SD, Berman David M (2019) Molecular profiling in muscle invasive bladder cancer: more than the sum of its parts. J Pathol 247:563\u2013573. \nhttps:\/\/doi.org\/10.1002\/path.5230","journal-title":"J Pathol"},{"key":"2593_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","volume":"143","author":"CC Guo","year":"2019","unstructured":"Guo CC, Czerniak B (2019) Bladder cancer in the genomic era. Arch Pathol Lab Med Jan 23 143:695\u2013704. \nhttps:\/\/doi.org\/10.5858\/arpa.2018-0329-RA","journal-title":"Arch Pathol Lab Med"},{"key":"2593_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.eururo.2018.09.006","volume":"75","author":"L Dyrskj\u00f8t","year":"2018","unstructured":"Dyrskj\u00f8t L (2018) Molecular subtypes of bladder cancer: academic exercise or clinical relevance? Eur Urol 75:433\u2013434. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2018.09.006","journal-title":"Eur Urol"},{"key":"2593_CR39","doi-asserted-by":"publisher","unstructured":"Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery J (2018) Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2018.08.027","DOI":"10.1016\/j.eururo.2018.08.027"},{"key":"2593_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","volume":"470","author":"J Breyer","year":"2017","unstructured":"Breyer J, Wirtz RM, Otto W et al (2017) In stage pT1 nonmuscle- invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch 470:267\u2013274","journal-title":"Virchows Arch"},{"key":"2593_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","volume":"75","author":"JI Warrick","year":"2019","unstructured":"Warrick JI, Sj\u00f6dahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ (2019) Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 75:18\u201322. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2018.09.003\n\n Epub 2018 Sep 25","journal-title":"Eur Urol"},{"key":"2593_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/his.13752","volume":"74","author":"A Lopez-Beltran","year":"2019","unstructured":"Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L (2019) Variants and new entities of bladder cancer. Histopathology 74:77\u201396","journal-title":"Histopathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02593-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-019-02593-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02593-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:17:40Z","timestamp":1592954260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-019-02593-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1007\/s00428-019-02593-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval from an institutional review board was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all the patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}